Skip to main content
. Author manuscript; available in PMC: 2009 Jun 19.
Published in final edited form as: Vaccine. 2008 Apr 30;26(26):3312–3321. doi: 10.1016/j.vaccine.2008.03.100

Figure 4. Susceptibility and resistance to SHIV89.6P infection correlates with MHC class IB haplotypes of Mauritian cynomolgus macaques.

Figure 4

Viral outcomes were defined as aviremic: never exhibiting a plasma viral load greater than 50 SHIV89.6P RNA copies per ml over the entire 52 week observation period; control viremia: viremia level during the chronic phase of infection dropped to an undetectable level (<50 copies/ml) on two or more occasions; remain viremic: plasma viremia persisted above detectable levels over the entire observation period.